Answers are grounded in this paper and cite their sources.
Review highlights improved oncologic outcomes with targeted therapies in non-small cell lung cancer, suggesting opportunities beyond standard chemotherapy.
The oncologic importance of an epidermal growth factor receptor (EGFR) mutation in the era of tyrosine-kinase inhibitors (TKIs) for patients with metastatic non-small cell lung cancer (NSCLC) cannot be overstated. The multiple positive trials evaluating gefitinib, erlotinib, and more recently osimeritinib as first line treatment of EGFR mutated NSCLC have revolutionized NSCLC management, with significantly improved oncologic and toxicity outcomes in this subset of patients (1-3).
No takes yet. Share an insight, caveat, or question.
Chau et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: